A REVIEW ON ANTIBODY OF ADUCANUMAB-REDUCES THE PROGRESSION OF ALZHEIMER DISEASE.

Alzheimer's disease is the most common form of dementia, affecting millions of people,
including family members who often act as caregivers. This devastating disease is believed
to account for 8% of total US healthcare spending, with medical and nursing costs
amounting to approximately $29 billion. . Alzheimer. The first monoclonal antibody,, to
recently receive US FDA accelerated approval for moderate AD is aducanumab. Future
therapies could be the first chemical approved to treat AD since 2003. The amyloid (A)
pathway is becoming increasingly implicated in the pathogenesis of AD as it has evolved
over time from a pathogen to a disease. - biological structure.The approval of aducanumab
is based on the reduction of the A-load in the brain, which serves as a direct marker for this
signaling pathway. The fully human IgG1 monoclonal antibody aducanumab (BIIB-037)
specifically binds to aggregated form A, inhibiting its matrix function and helping to clear
plaque. There are three human trials that ended prematurely. Epidemiology,
pathophysiology, and risk factors are discussed in this review, and currently aducanumab is
the only drug approved for food and drug administration that slows disease progression.